Lab-Free Diagnostics Startup Intu Raises $1.2M

Jan de Vries · 2026-06-26

A Leipzig-based startup called Intu Diagnostics just made a big leap toward bringing lab-quality testing into your home. The company, which builds a platform for completely lab-free molecular diagnostics, has closed a $1.2 million strategic bridge round (converted from €1.1 million). That brings their total funding to over $3.3 million. The round was backed by BSV Ventures, SAB (Saxonian Development Bank), and a group of business angels. So what's the money for? Intu plans to strengthen its intellectual property, run pilot manufacturing trials, and get ready for scale-up ahead of a planned Seed round. ### The Big Idea: Lab-to-Go Here's the vision: a pocket-sized, power-free diagnostic platform that works anywhere. No lab, no electricity, no central facility required. The company calls it "LAB-TO-GO" and claims it can deliver doctor's office-level reliability straight to a patient's door. "The clinical laboratory is expanding," the company said in a statement. "It no longer requires a physical facility, a power grid, or a centralised destination." Think about what that means for people in rural areas, developing countries, or even just busy parents who can't easily get to a clinic. You could test for infectious diseases at home, in a pharmacy, or in a mobile clinic, and get results that are as reliable as those from a traditional lab. ### The Funding Landscape Intu's bridge round is part of a bigger trend. In 2026, diagnostics, molecular pathology, biosensing, and related HealthTech companies raised about $92 million (€84 million) in total. Add Intu's new round, and that number jumps to around $93.3 million. Some of the closest competitors in this space include: - **ShanX Medtech** – Raised $26.3 million for in-vitro antimicrobial susceptibility testing. - **Xyall** – Raised $8.3 million for molecular pathology automation. - **Moonlight AI** – Raised $3.1 million for AI-enabled clinical diagnostics. - **Xsensio** – Raised $6.6 million for continuous biochemical monitoring. - **NanoStruct** (Würzburg, Germany) – Raised $2.9 million for rapid bacterial detection. ### What Intu is Actually Building Founded in 2023 as a spin-off from the Fraunhofer Society, Intu Diagnostics is building a decentralized molecular diagnostics platform. Their goal? Make high-quality infectious disease testing accessible outside of centralized labs. The technology is designed to work without lab infrastructure, specialized equipment, or electricity. That's a game-changer for resource-limited settings. Their first application focuses on HPV testing in women's health. Why HPV? Because accessible, reliable, and early testing can have a massive impact on preventing cervical cancer. But the platform is adaptable, so it could eventually test for multiple infectious diseases. ### What This Round Means for the Future This bridge round lets Intu hit some critical milestones: - Strengthen IP protection - Run pilot manufacturing trials - Validate their technology - Prepare for a full Seed round If they succeed, we could see a world where testing for HPV, strep throat, flu, and other infections happens in minutes at your local pharmacy or even in your living room. No more waiting days for lab results or driving miles to a clinic. The company is essentially trying to democratize diagnostics, and this funding is a big step in that direction.